nodes	percent_of_prediction	percent_of_DWPC	metapath
Bexarotene—CYP2C9—Estropipate—osteoporosis	0.0901	0.195	CbGbCtD
Bexarotene—CYP3A4—Estropipate—osteoporosis	0.0524	0.113	CbGbCtD
Bexarotene—CYP3A4—Calcitriol—osteoporosis	0.0524	0.113	CbGbCtD
Bexarotene—CYP2C9—Cholecalciferol—osteoporosis	0.0464	0.1	CbGbCtD
Bexarotene—CYP3A4—Ergocalciferol—osteoporosis	0.0419	0.0905	CbGbCtD
Bexarotene—CYP2C9—Estradiol—osteoporosis	0.0374	0.0808	CbGbCtD
Bexarotene—CYP3A4—Raloxifene—osteoporosis	0.0349	0.0755	CbGbCtD
Bexarotene—CYP3A4—Ethinyl Estradiol—osteoporosis	0.0338	0.0729	CbGbCtD
Bexarotene—CYP3A4—Cholecalciferol—osteoporosis	0.027	0.0583	CbGbCtD
Bexarotene—CYP3A4—Conjugated Estrogens—osteoporosis	0.0248	0.0535	CbGbCtD
Bexarotene—CYP3A4—Estradiol—osteoporosis	0.0217	0.047	CbGbCtD
Bexarotene—RXRB—Nuclear Receptors—ESR2—osteoporosis	0.00215	0.0143	CbGpPWpGaD
Bexarotene—RXRB—Retinoic acid receptors-mediated signaling—VDR—osteoporosis	0.00206	0.0137	CbGpPWpGaD
Bexarotene—RXRA—Bile acid and bile salt metabolism—CYP27A1—osteoporosis	0.00202	0.0134	CbGpPWpGaD
Bexarotene—RXRG—Nuclear Receptors—VDR—osteoporosis	0.00182	0.012	CbGpPWpGaD
Bexarotene—RXRG—Nuclear Receptor transcription pathway—ESR2—osteoporosis	0.00181	0.012	CbGpPWpGaD
Bexarotene—RXRA—Pyruvate metabolism and Citric Acid (TCA) cycle—IDH2—osteoporosis	0.0018	0.0119	CbGpPWpGaD
Bexarotene—RXRB—Nuclear Receptors—VDR—osteoporosis	0.00171	0.0113	CbGpPWpGaD
Bexarotene—RXRB—Nuclear Receptor transcription pathway—ESR2—osteoporosis	0.0017	0.0113	CbGpPWpGaD
Bexarotene—RXRA—Endogenous sterols—CYP19A1—osteoporosis	0.00152	0.0101	CbGpPWpGaD
Bexarotene—RXRG—Nuclear Receptor transcription pathway—VDR—osteoporosis	0.00144	0.00952	CbGpPWpGaD
Bexarotene—RXRG—Nuclear Receptors—ESR1—osteoporosis	0.00139	0.0092	CbGpPWpGaD
Bexarotene—RXRB—Nuclear Receptor transcription pathway—VDR—osteoporosis	0.00135	0.00895	CbGpPWpGaD
Bexarotene—RXRA—Cytochrome P450 - arranged by substrate type—CYP27A1—osteoporosis	0.00134	0.00892	CbGpPWpGaD
Bexarotene—RXRB—Nuclear Receptors—ESR1—osteoporosis	0.0013	0.00865	CbGpPWpGaD
Bexarotene—RXRA—Farnesoid X Receptor  Pathway—IRS2—osteoporosis	0.00127	0.00841	CbGpPWpGaD
Bexarotene—RXRA—RXR and RAR heterodimerization with other nuclear receptor—VDR—osteoporosis	0.00121	0.008	CbGpPWpGaD
Bexarotene—RXRA—Transcription factor regulation in adipogenesis—IRS2—osteoporosis	0.00113	0.00747	CbGpPWpGaD
Bexarotene—RXRA—Nuclear Receptors—ESR2—osteoporosis	0.00112	0.00744	CbGpPWpGaD
Bexarotene—RXRG—Adipogenesis—WNT1—osteoporosis	0.00112	0.00743	CbGpPWpGaD
Bexarotene—RXRA—Transcription factor regulation in adipogenesis—LEP—osteoporosis	0.0011	0.00731	CbGpPWpGaD
Bexarotene—RXRG—Nuclear Receptor transcription pathway—ESR1—osteoporosis	0.0011	0.00727	CbGpPWpGaD
Bexarotene—RXRA—Phase 1 - Functionalization of compounds—CYP27A1—osteoporosis	0.00109	0.00723	CbGpPWpGaD
Bexarotene—RXRA—Retinoic acid receptors-mediated signaling—VDR—osteoporosis	0.00108	0.00713	CbGpPWpGaD
Bexarotene—RXRB—Nuclear Receptor transcription pathway—ESR1—osteoporosis	0.00103	0.00684	CbGpPWpGaD
Bexarotene—RXRG—Adipogenesis—BMP2—osteoporosis	0.00101	0.00672	CbGpPWpGaD
Bexarotene—RXRA—Orphan transporters—ANXA2—osteoporosis	0.000991	0.00657	CbGpPWpGaD
Bexarotene—RXRA—Transcription factor regulation in adipogenesis—IRS1—osteoporosis	0.000984	0.00653	CbGpPWpGaD
Bexarotene—RXRG—RXR and RAR heterodimerization with other nuclear receptor—TGFB1—osteoporosis	0.000975	0.00647	CbGpPWpGaD
Bexarotene—RXRA—Fatty acid, triacylglycerol, and ketone body metabolism—GPD2—osteoporosis	0.000922	0.00611	CbGpPWpGaD
Bexarotene—RXRB—RXR and RAR heterodimerization with other nuclear receptor—TGFB1—osteoporosis	0.000917	0.00608	CbGpPWpGaD
Bexarotene—RXRA—Endogenous sterols—POMC—osteoporosis	0.000914	0.00606	CbGpPWpGaD
Bexarotene—RXRG—RXR and RAR heterodimerization with other nuclear receptor—TNF—osteoporosis	0.000911	0.00604	CbGpPWpGaD
Bexarotene—RXRA—Nuclear Receptors—VDR—osteoporosis	0.00089	0.0059	CbGpPWpGaD
Bexarotene—RXRA—Nuclear Receptor transcription pathway—ESR2—osteoporosis	0.000886	0.00588	CbGpPWpGaD
Bexarotene—RXRB—RXR and RAR heterodimerization with other nuclear receptor—TNF—osteoporosis	0.000856	0.00568	CbGpPWpGaD
Bexarotene—RXRA—Transcriptional regulation of white adipocyte differentiation—WNT1—osteoporosis	0.000835	0.00554	CbGpPWpGaD
Bexarotene—RXRA—Fatty acid, triacylglycerol, and ketone body metabolism—OXCT1—osteoporosis	0.000717	0.00475	CbGpPWpGaD
Bexarotene—RXRA—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	0.000706	0.00469	CbGpPWpGaD
Bexarotene—RXRA—Nuclear Receptor transcription pathway—VDR—osteoporosis	0.000703	0.00466	CbGpPWpGaD
Bexarotene—RXRA—The citric acid (TCA) cycle and respiratory electron transport—IDH2—osteoporosis	0.000698	0.00463	CbGpPWpGaD
Bexarotene—RXRA—Nuclear Receptors—ESR1—osteoporosis	0.00068	0.00451	CbGpPWpGaD
Bexarotene—RXRA—Biological oxidations—CYP27A1—osteoporosis	0.000579	0.00384	CbGpPWpGaD
Bexarotene—RXRA—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	0.000573	0.0038	CbGpPWpGaD
Bexarotene—RXRG—Adipogenesis—IRS2—osteoporosis	0.000555	0.00368	CbGpPWpGaD
Bexarotene—RXRA—Adipogenesis—WNT1—osteoporosis	0.000549	0.00364	CbGpPWpGaD
Bexarotene—RXRG—Adipogenesis—LEP—osteoporosis	0.000543	0.0036	CbGpPWpGaD
Bexarotene—RXRA—Nuclear Receptor transcription pathway—ESR1—osteoporosis	0.000537	0.00356	CbGpPWpGaD
Bexarotene—RXRA—Transcription factor regulation in adipogenesis—TNF—osteoporosis	0.00051	0.00338	CbGpPWpGaD
Bexarotene—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP27A1—osteoporosis	0.000502	0.00333	CbGpPWpGaD
Bexarotene—RXRA—Adipogenesis—BMP2—osteoporosis	0.000497	0.00329	CbGpPWpGaD
Bexarotene—CYP2C9—Oxidation by Cytochrome P450—CYP27A1—osteoporosis	0.000495	0.00329	CbGpPWpGaD
Bexarotene—RXRG—Adipogenesis—IRS1—osteoporosis	0.000485	0.00322	CbGpPWpGaD
Bexarotene—RXRA—PPAR Alpha Pathway—MYC—osteoporosis	0.000479	0.00318	CbGpPWpGaD
Bexarotene—RXRA—RXR and RAR heterodimerization with other nuclear receptor—TGFB1—osteoporosis	0.000478	0.00317	CbGpPWpGaD
Bexarotene—RXRG—Adipogenesis—IGF1—osteoporosis	0.000449	0.00298	CbGpPWpGaD
Bexarotene—RXRA—RXR and RAR heterodimerization with other nuclear receptor—TNF—osteoporosis	0.000446	0.00296	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—RAP1A—osteoporosis	0.000433	0.00287	CbGpPWpGaD
Bexarotene—RXRA—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	0.000425	0.00282	CbGpPWpGaD
Bexarotene—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—osteoporosis	0.000417	0.00277	CbGpPWpGaD
Bexarotene—RXRA—Transcription factor regulation in adipogenesis—IL6—osteoporosis	0.000412	0.00273	CbGpPWpGaD
Bexarotene—CYP2C9—Phase 1 - Functionalization of compounds—CYP27A1—osteoporosis	0.000407	0.0027	CbGpPWpGaD
Bexarotene—RXRA—Transcriptional regulation of white adipocyte differentiation—LEP—osteoporosis	0.000405	0.00269	CbGpPWpGaD
Bexarotene—RXRG—Gene Expression—U2AF1—osteoporosis	0.000392	0.0026	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—CAP1—osteoporosis	0.000392	0.0026	CbGpPWpGaD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—FDPS—osteoporosis	0.000387	0.00257	CbGpPWpGaD
Bexarotene—RXRB—Gene Expression—U2AF1—osteoporosis	0.000369	0.00245	CbGpPWpGaD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—GPD2—osteoporosis	0.000367	0.00243	CbGpPWpGaD
Bexarotene—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—osteoporosis	0.000363	0.00241	CbGpPWpGaD
Bexarotene—RXRA—Phase 1 - Functionalization of compounds—POMC—osteoporosis	0.000344	0.00228	CbGpPWpGaD
Bexarotene—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP27A1—osteoporosis	0.000331	0.0022	CbGpPWpGaD
Bexarotene—CYP3A4—Oxidation by Cytochrome P450—CYP27A1—osteoporosis	0.000327	0.00217	CbGpPWpGaD
Bexarotene—RXRG—Generic Transcription Pathway—ESR2—osteoporosis	0.000312	0.00207	CbGpPWpGaD
Bexarotene—CYP3A4—Farnesoid X Receptor  Pathway—IRS2—osteoporosis	0.000312	0.00207	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—ESR2—osteoporosis	0.000308	0.00204	CbGpPWpGaD
Bexarotene—RXRA—Biological oxidations—CYP19A1—osteoporosis	0.000304	0.00202	CbGpPWpGaD
Bexarotene—RXRB—Generic Transcription Pathway—ESR2—osteoporosis	0.000294	0.00195	CbGpPWpGaD
Bexarotene—RXRG—Gene Expression—RPL24—osteoporosis	0.000292	0.00193	CbGpPWpGaD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—OXCT1—osteoporosis	0.000285	0.00189	CbGpPWpGaD
Bexarotene—RXRA—NRF2 pathway—AGER—osteoporosis	0.000284	0.00189	CbGpPWpGaD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—MGLL—osteoporosis	0.000278	0.00185	CbGpPWpGaD
Bexarotene—RXRB—Gene Expression—RPL24—osteoporosis	0.000274	0.00182	CbGpPWpGaD
Bexarotene—RXRA—Adipogenesis—IRS2—osteoporosis	0.000272	0.0018	CbGpPWpGaD
Bexarotene—RXRG—Adipogenesis—TGFB1—osteoporosis	0.000269	0.00179	CbGpPWpGaD
Bexarotene—CYP3A4—Phase 1 - Functionalization of compounds—CYP27A1—osteoporosis	0.000268	0.00178	CbGpPWpGaD
Bexarotene—RXRA—Adipogenesis—LEP—osteoporosis	0.000266	0.00177	CbGpPWpGaD
Bexarotene—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	0.000264	0.00175	CbGpPWpGaD
Bexarotene—CYP2C9—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	0.00026	0.00173	CbGpPWpGaD
Bexarotene—RXRG—Adipogenesis—TNF—osteoporosis	0.000251	0.00167	CbGpPWpGaD
Bexarotene—CYP2C9—Arachidonic acid metabolism—GPX1—osteoporosis	0.000248	0.00165	CbGpPWpGaD
Bexarotene—RXRG—Generic Transcription Pathway—VDR—osteoporosis	0.000248	0.00164	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—TLN1—osteoporosis	0.000246	0.00163	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—ACTG1—osteoporosis	0.000242	0.00161	CbGpPWpGaD
Bexarotene—RXRA—Transmembrane transport of small molecules—ANXA2—osteoporosis	0.000242	0.0016	CbGpPWpGaD
Bexarotene—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—osteoporosis	0.000239	0.00159	CbGpPWpGaD
Bexarotene—RXRA—Adipogenesis—IRS1—osteoporosis	0.000237	0.00158	CbGpPWpGaD
Bexarotene—RXRB—Generic Transcription Pathway—VDR—osteoporosis	0.000233	0.00155	CbGpPWpGaD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	0.000222	0.00148	CbGpPWpGaD
Bexarotene—RXRA—Adipogenesis—IGF1—osteoporosis	0.00022	0.00146	CbGpPWpGaD
Bexarotene—CYP2C9—Biological oxidations—CYP27A1—osteoporosis	0.000216	0.00143	CbGpPWpGaD
Bexarotene—CYP3A4—Tryptophan metabolism—CYP19A1—osteoporosis	0.000215	0.00143	CbGpPWpGaD
Bexarotene—CYP2C9—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	0.000214	0.00142	CbGpPWpGaD
Bexarotene—CYP2C9—Metapathway biotransformation—CYP27A1—osteoporosis	0.000213	0.00141	CbGpPWpGaD
Bexarotene—Myalgia—Zoledronate—osteoporosis	0.000207	0.000537	CcSEcCtD
Bexarotene—Palpitations—Conjugated Estrogens—osteoporosis	0.000207	0.000536	CcSEcCtD
Bexarotene—Insomnia—Risedronate—osteoporosis	0.000207	0.000536	CcSEcCtD
Bexarotene—Anxiety—Zoledronate—osteoporosis	0.000207	0.000535	CcSEcCtD
Bexarotene—Loss of consciousness—Conjugated Estrogens—osteoporosis	0.000206	0.000534	CcSEcCtD
Bexarotene—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	0.000206	0.000533	CcSEcCtD
Bexarotene—Paraesthesia—Risedronate—osteoporosis	0.000206	0.000532	CcSEcCtD
Bexarotene—Pruritus—Estropipate—osteoporosis	0.000205	0.00053	CcSEcCtD
Bexarotene—Discomfort—Zoledronate—osteoporosis	0.000205	0.00053	CcSEcCtD
Bexarotene—Asthenia—Alendronate—osteoporosis	0.000205	0.00053	CcSEcCtD
Bexarotene—Hypersensitivity—Ibandronate—osteoporosis	0.000205	0.00053	CcSEcCtD
Bexarotene—Cough—Conjugated Estrogens—osteoporosis	0.000205	0.00053	CcSEcCtD
Bexarotene—Dyspnoea—Risedronate—osteoporosis	0.000204	0.000528	CcSEcCtD
Bexarotene—Dry mouth—Zoledronate—osteoporosis	0.000203	0.000525	CcSEcCtD
Bexarotene—RXRG—Adipogenesis—IL6—osteoporosis	0.000203	0.00135	CbGpPWpGaD
Bexarotene—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.000203	0.000525	CcSEcCtD
Bexarotene—Fatigue—Ethinyl Estradiol—osteoporosis	0.000203	0.000524	CcSEcCtD
Bexarotene—Pruritus—Alendronate—osteoporosis	0.000202	0.000523	CcSEcCtD
Bexarotene—Dyspepsia—Risedronate—osteoporosis	0.000202	0.000522	CcSEcCtD
Bexarotene—Eye disorder—Estradiol—osteoporosis	0.000202	0.000522	CcSEcCtD
Bexarotene—Tinnitus—Estradiol—osteoporosis	0.000201	0.00052	CcSEcCtD
Bexarotene—Constipation—Ethinyl Estradiol—osteoporosis	0.000201	0.00052	CcSEcCtD
Bexarotene—RXRA—Transcriptional regulation of white adipocyte differentiation—TGFB1—osteoporosis	0.000201	0.00133	CbGpPWpGaD
Bexarotene—Confusional state—Zoledronate—osteoporosis	0.000201	0.000519	CcSEcCtD
Bexarotene—Hypersensitivity—Calcitriol—osteoporosis	0.0002	0.000519	CcSEcCtD
Bexarotene—Cardiac disorder—Estradiol—osteoporosis	0.0002	0.000518	CcSEcCtD
Bexarotene—Arthralgia—Conjugated Estrogens—osteoporosis	0.0002	0.000517	CcSEcCtD
Bexarotene—Chest pain—Conjugated Estrogens—osteoporosis	0.0002	0.000517	CcSEcCtD
Bexarotene—Myalgia—Conjugated Estrogens—osteoporosis	0.0002	0.000517	CcSEcCtD
Bexarotene—Asthenia—Ibandronate—osteoporosis	0.000199	0.000516	CcSEcCtD
Bexarotene—Anxiety—Conjugated Estrogens—osteoporosis	0.000199	0.000515	CcSEcCtD
Bexarotene—Nausea—Etidronic acid—osteoporosis	0.000199	0.000515	CcSEcCtD
Bexarotene—Oedema—Zoledronate—osteoporosis	0.000199	0.000515	CcSEcCtD
Bexarotene—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.000198	0.000513	CcSEcCtD
Bexarotene—Musculoskeletal discomfort—Pamidronate—osteoporosis	0.000198	0.000513	CcSEcCtD
Bexarotene—Diarrhoea—Estropipate—osteoporosis	0.000198	0.000513	CcSEcCtD
Bexarotene—Gastrointestinal disorder—Risedronate—osteoporosis	0.000198	0.000512	CcSEcCtD
Bexarotene—Infection—Zoledronate—osteoporosis	0.000198	0.000511	CcSEcCtD
Bexarotene—Fatigue—Risedronate—osteoporosis	0.000197	0.000511	CcSEcCtD
Bexarotene—Insomnia—Pamidronate—osteoporosis	0.000197	0.000509	CcSEcCtD
Bexarotene—Pruritus—Ibandronate—osteoporosis	0.000197	0.000509	CcSEcCtD
Bexarotene—Constipation—Risedronate—osteoporosis	0.000196	0.000507	CcSEcCtD
Bexarotene—Pain—Risedronate—osteoporosis	0.000196	0.000507	CcSEcCtD
Bexarotene—Angiopathy—Estradiol—osteoporosis	0.000196	0.000506	CcSEcCtD
Bexarotene—Shock—Zoledronate—osteoporosis	0.000196	0.000506	CcSEcCtD
Bexarotene—Paraesthesia—Pamidronate—osteoporosis	0.000195	0.000506	CcSEcCtD
Bexarotene—Diarrhoea—Alendronate—osteoporosis	0.000195	0.000505	CcSEcCtD
Bexarotene—Asthenia—Calcitriol—osteoporosis	0.000195	0.000505	CcSEcCtD
Bexarotene—Nervous system disorder—Zoledronate—osteoporosis	0.000195	0.000505	CcSEcCtD
Bexarotene—Thrombocytopenia—Zoledronate—osteoporosis	0.000195	0.000504	CcSEcCtD
Bexarotene—Dyspnoea—Pamidronate—osteoporosis	0.000194	0.000502	CcSEcCtD
Bexarotene—Tachycardia—Zoledronate—osteoporosis	0.000194	0.000502	CcSEcCtD
Bexarotene—Feeling abnormal—Ethinyl Estradiol—osteoporosis	0.000194	0.000501	CcSEcCtD
Bexarotene—Chills—Estradiol—osteoporosis	0.000194	0.000501	CcSEcCtD
Bexarotene—Somnolence—Pamidronate—osteoporosis	0.000194	0.000501	CcSEcCtD
Bexarotene—Skin disorder—Zoledronate—osteoporosis	0.000193	0.0005	CcSEcCtD
Bexarotene—Pruritus—Calcitriol—osteoporosis	0.000192	0.000498	CcSEcCtD
Bexarotene—RXRA—Gene Expression—U2AF1—osteoporosis	0.000192	0.00128	CbGpPWpGaD
Bexarotene—Hyperhidrosis—Zoledronate—osteoporosis	0.000192	0.000497	CcSEcCtD
Bexarotene—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	0.000192	0.000497	CcSEcCtD
Bexarotene—Diarrhoea—Raloxifene—osteoporosis	0.000192	0.000497	CcSEcCtD
Bexarotene—Dyspepsia—Pamidronate—osteoporosis	0.000192	0.000496	CcSEcCtD
Bexarotene—Dizziness—Estropipate—osteoporosis	0.000192	0.000496	CcSEcCtD
Bexarotene—Oedema—Conjugated Estrogens—osteoporosis	0.000191	0.000495	CcSEcCtD
Bexarotene—Alopecia—Estradiol—osteoporosis	0.000191	0.000493	CcSEcCtD
Bexarotene—Infection—Conjugated Estrogens—osteoporosis	0.00019	0.000492	CcSEcCtD
Bexarotene—Diarrhoea—Ibandronate—osteoporosis	0.00019	0.000492	CcSEcCtD
Bexarotene—Anorexia—Zoledronate—osteoporosis	0.00019	0.00049	CcSEcCtD
Bexarotene—RXRG—Generic Transcription Pathway—ESR1—osteoporosis	0.000189	0.00126	CbGpPWpGaD
Bexarotene—Decreased appetite—Pamidronate—osteoporosis	0.000189	0.00049	CcSEcCtD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	0.000189	0.00125	CbGpPWpGaD
Bexarotene—Dizziness—Alendronate—osteoporosis	0.000189	0.000488	CcSEcCtD
Bexarotene—RXRA—Developmental Biology—WNT1—osteoporosis	0.000189	0.00125	CbGpPWpGaD
Bexarotene—Shock—Conjugated Estrogens—osteoporosis	0.000188	0.000487	CcSEcCtD
Bexarotene—Gastrointestinal disorder—Pamidronate—osteoporosis	0.000188	0.000486	CcSEcCtD
Bexarotene—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.000188	0.000486	CcSEcCtD
Bexarotene—Erythema—Estradiol—osteoporosis	0.000188	0.000486	CcSEcCtD
Bexarotene—Malnutrition—Estradiol—osteoporosis	0.000188	0.000486	CcSEcCtD
Bexarotene—Fatigue—Pamidronate—osteoporosis	0.000188	0.000486	CcSEcCtD
Bexarotene—Gastrointestinal pain—Risedronate—osteoporosis	0.000187	0.000485	CcSEcCtD
Bexarotene—RXRA—Transcriptional regulation of white adipocyte differentiation—TNF—osteoporosis	0.000187	0.00124	CbGpPWpGaD
Bexarotene—Tachycardia—Conjugated Estrogens—osteoporosis	0.000187	0.000484	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—ESR1—osteoporosis	0.000187	0.00124	CbGpPWpGaD
Bexarotene—Constipation—Pamidronate—osteoporosis	0.000186	0.000482	CcSEcCtD
Bexarotene—Pain—Pamidronate—osteoporosis	0.000186	0.000482	CcSEcCtD
Bexarotene—Diarrhoea—Calcitriol—osteoporosis	0.000186	0.000482	CcSEcCtD
Bexarotene—Skin disorder—Conjugated Estrogens—osteoporosis	0.000186	0.000481	CcSEcCtD
Bexarotene—Abdominal pain—Ethinyl Estradiol—osteoporosis	0.000186	0.00048	CcSEcCtD
Bexarotene—Body temperature increased—Ethinyl Estradiol—osteoporosis	0.000186	0.00048	CcSEcCtD
Bexarotene—Dizziness—Raloxifene—osteoporosis	0.000186	0.00048	CcSEcCtD
Bexarotene—Hyperhidrosis—Conjugated Estrogens—osteoporosis	0.000185	0.000479	CcSEcCtD
Bexarotene—Flatulence—Estradiol—osteoporosis	0.000185	0.000479	CcSEcCtD
Bexarotene—Tension—Estradiol—osteoporosis	0.000184	0.000477	CcSEcCtD
Bexarotene—Vomiting—Estropipate—osteoporosis	0.000184	0.000477	CcSEcCtD
Bexarotene—Dysgeusia—Estradiol—osteoporosis	0.000184	0.000476	CcSEcCtD
Bexarotene—Dizziness—Ibandronate—osteoporosis	0.000184	0.000475	CcSEcCtD
Bexarotene—RXRA—Biological oxidations—POMC—osteoporosis	0.000183	0.00121	CbGpPWpGaD
Bexarotene—Rash—Estropipate—osteoporosis	0.000183	0.000473	CcSEcCtD
Bexarotene—Dermatitis—Estropipate—osteoporosis	0.000183	0.000472	CcSEcCtD
Bexarotene—Anorexia—Conjugated Estrogens—osteoporosis	0.000183	0.000472	CcSEcCtD
Bexarotene—Nervousness—Estradiol—osteoporosis	0.000182	0.000472	CcSEcCtD
Bexarotene—Back pain—Estradiol—osteoporosis	0.000182	0.00047	CcSEcCtD
Bexarotene—Headache—Estropipate—osteoporosis	0.000182	0.00047	CcSEcCtD
Bexarotene—Vomiting—Alendronate—osteoporosis	0.000181	0.00047	CcSEcCtD
Bexarotene—Musculoskeletal discomfort—Zoledronate—osteoporosis	0.000181	0.000469	CcSEcCtD
Bexarotene—Abdominal pain—Risedronate—osteoporosis	0.000181	0.000468	CcSEcCtD
Bexarotene—Body temperature increased—Risedronate—osteoporosis	0.000181	0.000468	CcSEcCtD
Bexarotene—Muscle spasms—Estradiol—osteoporosis	0.000181	0.000467	CcSEcCtD
Bexarotene—Rash—Alendronate—osteoporosis	0.00018	0.000466	CcSEcCtD
Bexarotene—Insomnia—Zoledronate—osteoporosis	0.00018	0.000465	CcSEcCtD
Bexarotene—Dermatitis—Alendronate—osteoporosis	0.00018	0.000465	CcSEcCtD
Bexarotene—Feeling abnormal—Pamidronate—osteoporosis	0.000179	0.000464	CcSEcCtD
Bexarotene—Headache—Alendronate—osteoporosis	0.000179	0.000463	CcSEcCtD
Bexarotene—Paraesthesia—Zoledronate—osteoporosis	0.000179	0.000462	CcSEcCtD
Bexarotene—Vomiting—Raloxifene—osteoporosis	0.000178	0.000462	CcSEcCtD
Bexarotene—RXRB—Generic Transcription Pathway—ESR1—osteoporosis	0.000178	0.00118	CbGpPWpGaD
Bexarotene—Gastrointestinal pain—Pamidronate—osteoporosis	0.000178	0.000461	CcSEcCtD
Bexarotene—Dyspnoea—Zoledronate—osteoporosis	0.000177	0.000459	CcSEcCtD
Bexarotene—Rash—Raloxifene—osteoporosis	0.000177	0.000458	CcSEcCtD
Bexarotene—Dermatitis—Raloxifene—osteoporosis	0.000177	0.000458	CcSEcCtD
Bexarotene—Somnolence—Zoledronate—osteoporosis	0.000177	0.000457	CcSEcCtD
Bexarotene—Vomiting—Ibandronate—osteoporosis	0.000177	0.000457	CcSEcCtD
Bexarotene—Headache—Raloxifene—osteoporosis	0.000176	0.000455	CcSEcCtD
Bexarotene—Rash—Ibandronate—osteoporosis	0.000175	0.000453	CcSEcCtD
Bexarotene—Dermatitis—Ibandronate—osteoporosis	0.000175	0.000453	CcSEcCtD
Bexarotene—Dyspepsia—Zoledronate—osteoporosis	0.000175	0.000453	CcSEcCtD
Bexarotene—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	0.000174	0.000451	CcSEcCtD
Bexarotene—Ill-defined disorder—Estradiol—osteoporosis	0.000174	0.000451	CcSEcCtD
Bexarotene—Headache—Ibandronate—osteoporosis	0.000174	0.00045	CcSEcCtD
Bexarotene—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	0.000174	0.00115	CbGpPWpGaD
Bexarotene—Insomnia—Conjugated Estrogens—osteoporosis	0.000173	0.000448	CcSEcCtD
Bexarotene—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.000173	0.000448	CcSEcCtD
Bexarotene—Vomiting—Calcitriol—osteoporosis	0.000173	0.000448	CcSEcCtD
Bexarotene—Decreased appetite—Zoledronate—osteoporosis	0.000173	0.000447	CcSEcCtD
Bexarotene—Agitation—Estradiol—osteoporosis	0.000173	0.000446	CcSEcCtD
Bexarotene—RXRA—Metabolism—PKM—osteoporosis	0.000172	0.00114	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—FDPS—osteoporosis	0.000172	0.00114	CbGpPWpGaD
Bexarotene—Nausea—Estropipate—osteoporosis	0.000172	0.000445	CcSEcCtD
Bexarotene—Abdominal pain—Pamidronate—osteoporosis	0.000172	0.000445	CcSEcCtD
Bexarotene—Body temperature increased—Pamidronate—osteoporosis	0.000172	0.000445	CcSEcCtD
Bexarotene—Paraesthesia—Conjugated Estrogens—osteoporosis	0.000172	0.000445	CcSEcCtD
Bexarotene—Gastrointestinal disorder—Zoledronate—osteoporosis	0.000172	0.000444	CcSEcCtD
Bexarotene—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	0.000172	0.00114	CbGpPWpGaD
Bexarotene—Rash—Calcitriol—osteoporosis	0.000172	0.000444	CcSEcCtD
Bexarotene—Fatigue—Zoledronate—osteoporosis	0.000171	0.000444	CcSEcCtD
Bexarotene—Dermatitis—Calcitriol—osteoporosis	0.000171	0.000443	CcSEcCtD
Bexarotene—Dyspnoea—Conjugated Estrogens—osteoporosis	0.000171	0.000442	CcSEcCtD
Bexarotene—Headache—Calcitriol—osteoporosis	0.00017	0.000441	CcSEcCtD
Bexarotene—Somnolence—Conjugated Estrogens—osteoporosis	0.00017	0.00044	CcSEcCtD
Bexarotene—Pain—Zoledronate—osteoporosis	0.00017	0.00044	CcSEcCtD
Bexarotene—Constipation—Zoledronate—osteoporosis	0.00017	0.00044	CcSEcCtD
Bexarotene—Nausea—Alendronate—osteoporosis	0.00017	0.000439	CcSEcCtD
Bexarotene—Malaise—Estradiol—osteoporosis	0.000169	0.000438	CcSEcCtD
Bexarotene—Hypersensitivity—Risedronate—osteoporosis	0.000169	0.000437	CcSEcCtD
Bexarotene—Vertigo—Estradiol—osteoporosis	0.000169	0.000437	CcSEcCtD
Bexarotene—Dyspepsia—Conjugated Estrogens—osteoporosis	0.000169	0.000436	CcSEcCtD
Bexarotene—Asthenia—Ethinyl Estradiol—osteoporosis	0.000169	0.000436	CcSEcCtD
Bexarotene—Syncope—Estradiol—osteoporosis	0.000168	0.000436	CcSEcCtD
Bexarotene—RXRG—Gene Expression—PSMA5—osteoporosis	0.000168	0.00112	CbGpPWpGaD
Bexarotene—RXRG—Gene Expression—PSMA2—osteoporosis	0.000168	0.00112	CbGpPWpGaD
Bexarotene—Nausea—Raloxifene—osteoporosis	0.000167	0.000431	CcSEcCtD
Bexarotene—Decreased appetite—Conjugated Estrogens—osteoporosis	0.000166	0.000431	CcSEcCtD
Bexarotene—Pruritus—Ethinyl Estradiol—osteoporosis	0.000166	0.00043	CcSEcCtD
Bexarotene—Palpitations—Estradiol—osteoporosis	0.000166	0.000429	CcSEcCtD
Bexarotene—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.000165	0.000428	CcSEcCtD
Bexarotene—Fatigue—Conjugated Estrogens—osteoporosis	0.000165	0.000427	CcSEcCtD
Bexarotene—Nausea—Ibandronate—osteoporosis	0.000165	0.000427	CcSEcCtD
Bexarotene—Loss of consciousness—Estradiol—osteoporosis	0.000165	0.000427	CcSEcCtD
Bexarotene—Asthenia—Risedronate—osteoporosis	0.000164	0.000425	CcSEcCtD
Bexarotene—Feeling abnormal—Zoledronate—osteoporosis	0.000164	0.000424	CcSEcCtD
Bexarotene—Cough—Estradiol—osteoporosis	0.000164	0.000424	CcSEcCtD
Bexarotene—Constipation—Conjugated Estrogens—osteoporosis	0.000164	0.000424	CcSEcCtD
Bexarotene—Pain—Conjugated Estrogens—osteoporosis	0.000164	0.000424	CcSEcCtD
Bexarotene—RXRA—Metabolism—PGLS—osteoporosis	0.000163	0.00108	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—GPD2—osteoporosis	0.000163	0.00108	CbGpPWpGaD
Bexarotene—Gastrointestinal pain—Zoledronate—osteoporosis	0.000163	0.000421	CcSEcCtD
Bexarotene—Hypertension—Estradiol—osteoporosis	0.000162	0.000419	CcSEcCtD
Bexarotene—Pruritus—Risedronate—osteoporosis	0.000162	0.000419	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—IGF1—osteoporosis	0.000162	0.00107	CbGpPWpGaD
Bexarotene—Nausea—Calcitriol—osteoporosis	0.000162	0.000418	CcSEcCtD
Bexarotene—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.000161	0.000416	CcSEcCtD
Bexarotene—Hypersensitivity—Pamidronate—osteoporosis	0.00016	0.000415	CcSEcCtD
Bexarotene—Arthralgia—Estradiol—osteoporosis	0.00016	0.000414	CcSEcCtD
Bexarotene—Chest pain—Estradiol—osteoporosis	0.00016	0.000414	CcSEcCtD
Bexarotene—Myalgia—Estradiol—osteoporosis	0.00016	0.000414	CcSEcCtD
Bexarotene—Anxiety—Estradiol—osteoporosis	0.000159	0.000412	CcSEcCtD
Bexarotene—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.000159	0.000411	CcSEcCtD
Bexarotene—CYP2C9—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	0.000158	0.00105	CbGpPWpGaD
Bexarotene—RXRB—Gene Expression—PSMA2—osteoporosis	0.000158	0.00105	CbGpPWpGaD
Bexarotene—RXRB—Gene Expression—PSMA5—osteoporosis	0.000158	0.00105	CbGpPWpGaD
Bexarotene—Discomfort—Estradiol—osteoporosis	0.000158	0.000409	CcSEcCtD
Bexarotene—Abdominal pain—Zoledronate—osteoporosis	0.000157	0.000407	CcSEcCtD
Bexarotene—Body temperature increased—Zoledronate—osteoporosis	0.000157	0.000407	CcSEcCtD
Bexarotene—Diarrhoea—Risedronate—osteoporosis	0.000157	0.000405	CcSEcCtD
Bexarotene—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	0.000157	0.000405	CcSEcCtD
Bexarotene—Dry mouth—Estradiol—osteoporosis	0.000156	0.000405	CcSEcCtD
Bexarotene—Asthenia—Pamidronate—osteoporosis	0.000156	0.000404	CcSEcCtD
Bexarotene—Dizziness—Ethinyl Estradiol—osteoporosis	0.000155	0.000402	CcSEcCtD
Bexarotene—Confusional state—Estradiol—osteoporosis	0.000155	0.0004	CcSEcCtD
Bexarotene—Pruritus—Pamidronate—osteoporosis	0.000154	0.000399	CcSEcCtD
Bexarotene—Oedema—Estradiol—osteoporosis	0.000153	0.000397	CcSEcCtD
Bexarotene—RXRA—Generic Transcription Pathway—ESR2—osteoporosis	0.000153	0.00102	CbGpPWpGaD
Bexarotene—Infection—Estradiol—osteoporosis	0.000152	0.000394	CcSEcCtD
Bexarotene—Dizziness—Risedronate—osteoporosis	0.000151	0.000392	CcSEcCtD
Bexarotene—Body temperature increased—Conjugated Estrogens—osteoporosis	0.000151	0.000392	CcSEcCtD
Bexarotene—Abdominal pain—Conjugated Estrogens—osteoporosis	0.000151	0.000392	CcSEcCtD
Bexarotene—Shock—Estradiol—osteoporosis	0.000151	0.00039	CcSEcCtD
Bexarotene—RXRG—Gene Expression—ESR2—osteoporosis	0.00015	0.000997	CbGpPWpGaD
Bexarotene—Nervous system disorder—Estradiol—osteoporosis	0.00015	0.000389	CcSEcCtD
Bexarotene—Tachycardia—Estradiol—osteoporosis	0.00015	0.000387	CcSEcCtD
Bexarotene—RXRA—Metabolism—ATIC—osteoporosis	0.000149	0.000992	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—PNP—osteoporosis	0.000149	0.000992	CbGpPWpGaD
Bexarotene—Vomiting—Ethinyl Estradiol—osteoporosis	0.000149	0.000386	CcSEcCtD
Bexarotene—Diarrhoea—Pamidronate—osteoporosis	0.000149	0.000385	CcSEcCtD
Bexarotene—Skin disorder—Estradiol—osteoporosis	0.000149	0.000385	CcSEcCtD
Bexarotene—Hyperhidrosis—Estradiol—osteoporosis	0.000148	0.000383	CcSEcCtD
Bexarotene—Rash—Ethinyl Estradiol—osteoporosis	0.000148	0.000383	CcSEcCtD
Bexarotene—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000148	0.000383	CcSEcCtD
Bexarotene—Headache—Ethinyl Estradiol—osteoporosis	0.000147	0.000381	CcSEcCtD
Bexarotene—Hypersensitivity—Zoledronate—osteoporosis	0.000147	0.000379	CcSEcCtD
Bexarotene—Vomiting—Risedronate—osteoporosis	0.000146	0.000377	CcSEcCtD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—FDPS—osteoporosis	0.000145	0.000959	CbGpPWpGaD
Bexarotene—Rash—Risedronate—osteoporosis	0.000144	0.000374	CcSEcCtD
Bexarotene—Dermatitis—Risedronate—osteoporosis	0.000144	0.000373	CcSEcCtD
Bexarotene—Dizziness—Pamidronate—osteoporosis	0.000144	0.000373	CcSEcCtD
Bexarotene—Headache—Risedronate—osteoporosis	0.000143	0.000371	CcSEcCtD
Bexarotene—RXRA—Gene Expression—RPL24—osteoporosis	0.000143	0.000948	CbGpPWpGaD
Bexarotene—Asthenia—Zoledronate—osteoporosis	0.000143	0.000369	CcSEcCtD
Bexarotene—CYP3A4—Biological oxidations—CYP27A1—osteoporosis	0.000143	0.000946	CbGpPWpGaD
Bexarotene—RXRB—Gene Expression—ESR2—osteoporosis	0.000141	0.000938	CbGpPWpGaD
Bexarotene—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.000141	0.000365	CcSEcCtD
Bexarotene—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	0.000141	0.000935	CbGpPWpGaD
Bexarotene—Pruritus—Zoledronate—osteoporosis	0.000141	0.000364	CcSEcCtD
Bexarotene—CYP3A4—Metapathway biotransformation—CYP27A1—osteoporosis	0.000141	0.000933	CbGpPWpGaD
Bexarotene—Musculoskeletal discomfort—Estradiol—osteoporosis	0.00014	0.000361	CcSEcCtD
Bexarotene—Nausea—Ethinyl Estradiol—osteoporosis	0.00014	0.000361	CcSEcCtD
Bexarotene—Insomnia—Estradiol—osteoporosis	0.000139	0.000359	CcSEcCtD
Bexarotene—Vomiting—Pamidronate—osteoporosis	0.000138	0.000358	CcSEcCtD
Bexarotene—Paraesthesia—Estradiol—osteoporosis	0.000138	0.000356	CcSEcCtD
Bexarotene—Asthenia—Conjugated Estrogens—osteoporosis	0.000137	0.000355	CcSEcCtD
Bexarotene—Rash—Pamidronate—osteoporosis	0.000137	0.000355	CcSEcCtD
Bexarotene—Dermatitis—Pamidronate—osteoporosis	0.000137	0.000355	CcSEcCtD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—GPD2—osteoporosis	0.000137	0.000909	CbGpPWpGaD
Bexarotene—Dyspnoea—Estradiol—osteoporosis	0.000137	0.000354	CcSEcCtD
Bexarotene—Headache—Pamidronate—osteoporosis	0.000136	0.000353	CcSEcCtD
Bexarotene—Somnolence—Estradiol—osteoporosis	0.000136	0.000353	CcSEcCtD
Bexarotene—Diarrhoea—Zoledronate—osteoporosis	0.000136	0.000352	CcSEcCtD
Bexarotene—Nausea—Risedronate—osteoporosis	0.000136	0.000352	CcSEcCtD
Bexarotene—Pruritus—Conjugated Estrogens—osteoporosis	0.000135	0.000351	CcSEcCtD
Bexarotene—Dyspepsia—Estradiol—osteoporosis	0.000135	0.000349	CcSEcCtD
Bexarotene—Decreased appetite—Estradiol—osteoporosis	0.000133	0.000345	CcSEcCtD
Bexarotene—Gastrointestinal disorder—Estradiol—osteoporosis	0.000132	0.000342	CcSEcCtD
Bexarotene—Fatigue—Estradiol—osteoporosis	0.000132	0.000342	CcSEcCtD
Bexarotene—RXRA—Adipogenesis—TGFB1—osteoporosis	0.000132	0.000875	CbGpPWpGaD
Bexarotene—Dizziness—Zoledronate—osteoporosis	0.000132	0.00034	CcSEcCtD
Bexarotene—Pain—Estradiol—osteoporosis	0.000131	0.000339	CcSEcCtD
Bexarotene—Constipation—Estradiol—osteoporosis	0.000131	0.000339	CcSEcCtD
Bexarotene—Diarrhoea—Conjugated Estrogens—osteoporosis	0.000131	0.000339	CcSEcCtD
Bexarotene—Nausea—Pamidronate—osteoporosis	0.000129	0.000335	CcSEcCtD
Bexarotene—CYP2C9—Phase 1 - Functionalization of compounds—POMC—osteoporosis	0.000128	0.000852	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—OXCT1—osteoporosis	0.000127	0.000843	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—CA2—osteoporosis	0.000127	0.000843	CbGpPWpGaD
Bexarotene—Dizziness—Conjugated Estrogens—osteoporosis	0.000127	0.000328	CcSEcCtD
Bexarotene—Vomiting—Zoledronate—osteoporosis	0.000126	0.000327	CcSEcCtD
Bexarotene—Feeling abnormal—Estradiol—osteoporosis	0.000126	0.000327	CcSEcCtD
Bexarotene—Rash—Zoledronate—osteoporosis	0.000125	0.000324	CcSEcCtD
Bexarotene—Gastrointestinal pain—Estradiol—osteoporosis	0.000125	0.000324	CcSEcCtD
Bexarotene—Dermatitis—Zoledronate—osteoporosis	0.000125	0.000324	CcSEcCtD
Bexarotene—Headache—Zoledronate—osteoporosis	0.000125	0.000322	CcSEcCtD
Bexarotene—RXRA—Metabolism—MGLL—osteoporosis	0.000124	0.000822	CbGpPWpGaD
Bexarotene—RXRA—Adipogenesis—TNF—osteoporosis	0.000123	0.000817	CbGpPWpGaD
Bexarotene—Vomiting—Conjugated Estrogens—osteoporosis	0.000122	0.000315	CcSEcCtD
Bexarotene—RXRA—Generic Transcription Pathway—VDR—osteoporosis	0.000121	0.000806	CbGpPWpGaD
Bexarotene—Abdominal pain—Estradiol—osteoporosis	0.000121	0.000313	CcSEcCtD
Bexarotene—Body temperature increased—Estradiol—osteoporosis	0.000121	0.000313	CcSEcCtD
Bexarotene—Rash—Conjugated Estrogens—osteoporosis	0.000121	0.000312	CcSEcCtD
Bexarotene—Dermatitis—Conjugated Estrogens—osteoporosis	0.000121	0.000312	CcSEcCtD
Bexarotene—RXRA—NRF2 pathway—TGFB1—osteoporosis	0.00012	0.000797	CbGpPWpGaD
Bexarotene—Headache—Conjugated Estrogens—osteoporosis	0.00012	0.00031	CcSEcCtD
Bexarotene—RXRG—Gene Expression—VDR—osteoporosis	0.000119	0.000792	CbGpPWpGaD
Bexarotene—Nausea—Zoledronate—osteoporosis	0.000118	0.000306	CcSEcCtD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	0.000117	0.000775	CbGpPWpGaD
Bexarotene—Nausea—Conjugated Estrogens—osteoporosis	0.000114	0.000294	CcSEcCtD
Bexarotene—CYP2C9—Biological oxidations—CYP19A1—osteoporosis	0.000114	0.000753	CbGpPWpGaD
Bexarotene—Hypersensitivity—Estradiol—osteoporosis	0.000113	0.000292	CcSEcCtD
Bexarotene—RXRB—Gene Expression—VDR—osteoporosis	0.000112	0.000744	CbGpPWpGaD
Bexarotene—CYP2C9—Metapathway biotransformation—CYP19A1—osteoporosis	0.000112	0.000743	CbGpPWpGaD
Bexarotene—Asthenia—Estradiol—osteoporosis	0.00011	0.000284	CcSEcCtD
Bexarotene—Pruritus—Estradiol—osteoporosis	0.000108	0.000281	CcSEcCtD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—OXCT1—osteoporosis	0.000107	0.000707	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—IDH2—osteoporosis	0.000105	0.000699	CbGpPWpGaD
Bexarotene—Diarrhoea—Estradiol—osteoporosis	0.000105	0.000271	CcSEcCtD
Bexarotene—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	0.000105	0.000693	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—MGLL—osteoporosis	0.000104	0.000689	CbGpPWpGaD
Bexarotene—Dizziness—Estradiol—osteoporosis	0.000101	0.000262	CcSEcCtD
Bexarotene—RXRA—Adipogenesis—IL6—osteoporosis	9.94e-05	0.000659	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—CYP27A1—osteoporosis	9.9e-05	0.000657	CbGpPWpGaD
Bexarotene—RXRG—Generic Transcription Pathway—MYC—osteoporosis	9.85e-05	0.000654	CbGpPWpGaD
Bexarotene—Vomiting—Estradiol—osteoporosis	9.74e-05	0.000252	CcSEcCtD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—MYC—osteoporosis	9.72e-05	0.000645	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—TGFB1—osteoporosis	9.69e-05	0.000643	CbGpPWpGaD
Bexarotene—Rash—Estradiol—osteoporosis	9.66e-05	0.00025	CcSEcCtD
Bexarotene—Dermatitis—Estradiol—osteoporosis	9.65e-05	0.00025	CcSEcCtD
Bexarotene—RXRA—Metabolism—ACP5—osteoporosis	9.63e-05	0.000639	CbGpPWpGaD
Bexarotene—Headache—Estradiol—osteoporosis	9.6e-05	0.000248	CcSEcCtD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	9.51e-05	0.000631	CbGpPWpGaD
Bexarotene—RXRA—Generic Transcription Pathway—ESR1—osteoporosis	9.28e-05	0.000616	CbGpPWpGaD
Bexarotene—RXRB—Generic Transcription Pathway—MYC—osteoporosis	9.26e-05	0.000614	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—LEP—osteoporosis	9.15e-05	0.000607	CbGpPWpGaD
Bexarotene—RXRG—Gene Expression—ESR1—osteoporosis	9.12e-05	0.000605	CbGpPWpGaD
Bexarotene—Nausea—Estradiol—osteoporosis	9.1e-05	0.000236	CcSEcCtD
Bexarotene—RXRA—Transmembrane transport of small molecules—ADCY5—osteoporosis	9.07e-05	0.000602	CbGpPWpGaD
Bexarotene—RXRA—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	9.05e-05	0.0006	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—TPI1—osteoporosis	8.96e-05	0.000594	CbGpPWpGaD
Bexarotene—RXRB—Gene Expression—ESR1—osteoporosis	8.57e-05	0.000569	CbGpPWpGaD
Bexarotene—CYP3A4—Phase 1 - Functionalization of compounds—POMC—osteoporosis	8.47e-05	0.000562	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—P4HB—osteoporosis	8.42e-05	0.000559	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	8.3e-05	0.000551	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—GAPDH—osteoporosis	8.26e-05	0.000548	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—PSMA5—osteoporosis	8.25e-05	0.000547	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—PSMA2—osteoporosis	8.25e-05	0.000547	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—RAP1A—osteoporosis	8.05e-05	0.000534	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—IL6R—osteoporosis	7.67e-05	0.000509	CbGpPWpGaD
Bexarotene—CYP3A4—Biological oxidations—CYP19A1—osteoporosis	7.49e-05	0.000497	CbGpPWpGaD
Bexarotene—CYP3A4—Metapathway biotransformation—CYP19A1—osteoporosis	7.39e-05	0.00049	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—ESR2—osteoporosis	7.37e-05	0.000489	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	7.06e-05	0.000468	CbGpPWpGaD
Bexarotene—RXRA—Metabolism of lipids and lipoproteins—POMC—osteoporosis	7.02e-05	0.000466	CbGpPWpGaD
Bexarotene—CYP2C9—Biological oxidations—POMC—osteoporosis	6.82e-05	0.000453	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—ENO1—osteoporosis	6.51e-05	0.000432	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—PKM—osteoporosis	6.44e-05	0.000427	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—FDPS—osteoporosis	6.44e-05	0.000427	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—PSMA2—osteoporosis	6.41e-05	0.000425	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—PSMA5—osteoporosis	6.41e-05	0.000425	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—PGLS—osteoporosis	6.1e-05	0.000405	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—GPD2—osteoporosis	6.1e-05	0.000405	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—VDR—osteoporosis	5.85e-05	0.000388	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—ATIC—osteoporosis	5.58e-05	0.00037	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—PNP—osteoporosis	5.58e-05	0.00037	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—CYP19A1—osteoporosis	5.2e-05	0.000345	CbGpPWpGaD
Bexarotene—RXRA—Generic Transcription Pathway—MYC—osteoporosis	4.83e-05	0.00032	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—CA2—osteoporosis	4.75e-05	0.000315	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—OXCT1—osteoporosis	4.75e-05	0.000315	CbGpPWpGaD
Bexarotene—RXRG—Gene Expression—MYC—osteoporosis	4.74e-05	0.000315	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—MGLL—osteoporosis	4.62e-05	0.000307	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—TGFB1—osteoporosis	4.53e-05	0.000301	CbGpPWpGaD
Bexarotene—CYP3A4—Biological oxidations—POMC—osteoporosis	4.5e-05	0.000299	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—ESR1—osteoporosis	4.47e-05	0.000296	CbGpPWpGaD
Bexarotene—RXRB—Gene Expression—MYC—osteoporosis	4.46e-05	0.000296	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	4.36e-05	0.000289	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—ADCY5—osteoporosis	4.25e-05	0.000282	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—PKM—osteoporosis	4.25e-05	0.000282	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—FDPS—osteoporosis	4.25e-05	0.000282	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—GPX1—osteoporosis	4.24e-05	0.000281	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—TNF—osteoporosis	4.23e-05	0.000281	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—PGLS—osteoporosis	4.02e-05	0.000267	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—GPD2—osteoporosis	4.02e-05	0.000267	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—IDH2—osteoporosis	3.93e-05	0.000261	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—MTHFR—osteoporosis	3.91e-05	0.000259	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—CYP27A1—osteoporosis	3.7e-05	0.000245	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—ATIC—osteoporosis	3.68e-05	0.000244	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—PNP—osteoporosis	3.68e-05	0.000244	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—ACP5—osteoporosis	3.6e-05	0.000239	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	3.55e-05	0.000236	CbGpPWpGaD
Bexarotene—RXRA—Developmental Biology—IL6—osteoporosis	3.42e-05	0.000227	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—TPI1—osteoporosis	3.34e-05	0.000222	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—P4HB—osteoporosis	3.14e-05	0.000209	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—CA2—osteoporosis	3.13e-05	0.000208	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—OXCT1—osteoporosis	3.13e-05	0.000208	CbGpPWpGaD
Bexarotene—RXRA—Metabolism—POMC—osteoporosis	3.13e-05	0.000207	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—GAPDH—osteoporosis	3.09e-05	0.000205	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—MGLL—osteoporosis	3.05e-05	0.000202	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—RAP1A—osteoporosis	3.01e-05	0.000199	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism of lipids and lipoproteins—POMC—osteoporosis	2.62e-05	0.000174	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—IDH2—osteoporosis	2.59e-05	0.000172	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—CYP27A1—osteoporosis	2.44e-05	0.000162	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—ENO1—osteoporosis	2.43e-05	0.000161	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—PSMA2—osteoporosis	2.39e-05	0.000159	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—PSMA5—osteoporosis	2.39e-05	0.000159	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—ACP5—osteoporosis	2.37e-05	0.000157	CbGpPWpGaD
Bexarotene—RXRA—Gene Expression—MYC—osteoporosis	2.32e-05	0.000154	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—TPI1—osteoporosis	2.21e-05	0.000146	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—P4HB—osteoporosis	2.07e-05	0.000138	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—GAPDH—osteoporosis	2.03e-05	0.000135	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—RAP1A—osteoporosis	1.98e-05	0.000131	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—CYP19A1—osteoporosis	1.94e-05	0.000129	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—ENO1—osteoporosis	1.6e-05	0.000106	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—ADCY5—osteoporosis	1.59e-05	0.000105	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—GPX1—osteoporosis	1.58e-05	0.000105	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—PSMA2—osteoporosis	1.58e-05	0.000105	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—PSMA5—osteoporosis	1.58e-05	0.000105	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—MTHFR—osteoporosis	1.46e-05	9.68e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—CYP19A1—osteoporosis	1.28e-05	8.5e-05	CbGpPWpGaD
Bexarotene—CYP2C9—Metabolism—POMC—osteoporosis	1.17e-05	7.74e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—ADCY5—osteoporosis	1.05e-05	6.94e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—GPX1—osteoporosis	1.04e-05	6.92e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—MTHFR—osteoporosis	9.62e-06	6.38e-05	CbGpPWpGaD
Bexarotene—CYP3A4—Metabolism—POMC—osteoporosis	7.7e-06	5.11e-05	CbGpPWpGaD
